BRIEF-Puma Biotechnology Intends To Modify Characteristics Summary In Neratinib Marketing Authorization Application

* PUMA BIOTECHNOLOGY INC SAYS IT MET WITH COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SCIENTIFIC ADVISORY GROUP ON ONCOLOGY